Cover Image
市場調查報告書

PharmaPoint:多發性硬化症 - 全球醫藥品的預測與市場分析

PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 296450
出版日期 內容資訊 英文 367 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:多發性硬化症 - 全球醫藥品的預測與市場分析 PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
出版日期: 2015年09月10日 內容資訊: 英文 367 Pages
簡介

多發性硬化症(MS)是慢性的發炎性神經疾病,其病理學的特徵為中樞神經系統的去髓鞘化,軸突離斷,神經退化。根治性療法依然相當困難,目前疾病管理是透過病理修飾療法(DMT),必須一生依靠藥物療法。

本報告提供全球MS治療藥市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物詳細內容資訊(產品說明,安全性,有效性),彙整SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
    • MS的分類
  • 症狀
    • 預測
    • QOL

第4章 流行病學

  • 危險因子
    • MS患者的家族MS發病風險為1∼5%
    • 女性MS發病的風險是2倍,但男性預後差
    • 白人比其他人種/民族得MS的風險高
    • 維他命D的預防效果,與出生地的緯度和月份有關
    • 環境暴露的時機會影響MS的風險
    • 吸二手煙會提高MS的風險,讓預後惡化
  • 合併症
    • 自體免疫疾病MS的合併症
    • 精神疾病預測將達MS患者的60%,並影響復發率
  • 全球趨勢
    • 北美
    • 歐洲
    • 亞洲
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • 流行病學預測
    • 患病人數
    • 患病人數:各年齡
    • 患病人數:性別
    • 發病數量
    • 發病數量:各年齡
    • 發病數量:性別
    • 亞型MS
  • 議論
    • 流行病學趨勢相關考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 診斷
  • 治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 加拿大
  • 中國
  • 印度

第6章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介 - 領導品牌
    • Betaseron/Betaferon
    • Avonex
    • Rebif
    • Copaxone
    • Tysabri
    • Gilenya/Imusera
    • Aubagio
    • 其他DMT

第7章 機會及未滿足需求

  • 概要
  • 未滿足需求
  • 未滿足需求的差距分析
  • 機會

第8章 開發平台評估

  • 概要
  • 臨床試驗設計
  • 臨床試驗:階段·各階段
  • 臨床開發中的潛力藥物

第9章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Biogen Idec
    • Teva Pharmaceutical Industries
    • Merck Serono (EMD Serono)
    • Sanofi
    • Bayer HealthCare Pharmaceuticals
    • Novartis International
    • Hoffmann-La Roche
    • GlaxoSmithKline

第10章 市場預測

  • 全球市場
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 加拿大
  • 中國
  • 印度

第11章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC89PIDR

Multiple Sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system which leads to neurological disability. The exact underlying cause of the disease is poorly understood; however, it appears to involve a complex combination of genetic susceptibility and a non-genetic trigger. The MS therapeutics market has entered an exciting phase, with an upsurge of available treatment options. Over the forecast period, patients are expected to continue to switch to the oral disease-modifying therapies (DMTs), lessening the stronghold of the established injectable treatments. There are also several promising products in the late-stage pipeline, with a diverse range of mechanisms offering clinical advantages intended to address unmet needs. Both pipeline and marketed DMTs are seeking approval for the treatment of progressive MS, which currently represents a significant unmet need. These factors are expected to increase treatment rates throughout the 10MM resulting, driving market growth. However, this will be largely offset by brand erosion due to the emergence of biosimilars and generic small molecules.

Highlights

Key Questions Answered

  • The MS market has experienced a paradigm shift with the launch of first-line oral DMTs and efficacious escalation therapies. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
  • The current late-stage MS pipeline is robust and diverse, with 13 products in Phase III. GlobalData has profiled nine DMT drug therapies, of which eight are anticipated to launch during the forecast period. What impact will these drugs have on the market? How will they affect the treatment algorithm for MS? Will these drugs fulfil any of the unmet needs for MS?
  • The diagnosis and management of MS is challenging, even for the most experienced neurologists. How does the diagnosis and management of MS differ amongst the 10MM? Which DMT treatments are most commonly prescribed in each market, and how will prescribing patterns change over the forecast period?

Key Findings

  • The main driver of growth in the MS market will be the introduction of novel DMT products over the forecast period. Drugs targeting clinical unmet needs; such as improved efficacy, more convenient administration, or progressive MS approval; will increase treatment rates and drive market growth.
  • There is a high disparity between treatments for RRMS and progressive MS amongst the currently available drugs and, despite its diversity, the late late-stage pipeline remains skewed towards RRMS. As such, the RRMS market will become increasingly competitive making it more difficult for new entrants to gain patient share.
  • The biggest barrier for growth in the MS market will be competition from generic/biosimilar products for key branded therapies. In particular, the launch of generic small-molecules will hamper future growth of the MS market.
  • Considerable opportunity remains for products that meet the unmet needs in the MS market. A drug that prevents disease progression and the accumulation of disability would be viewed favourably. Additionally, targeting progressive MS will be an ongoing opportunity.

Scope

  • Overview of MS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized MS market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the MS therapeutics market.
  • Pipeline analysis: focus on nine late-stage pipeline MS drugs, discussing emerging trends as well as an overview of earlier phase drugs and a top-line analysis of therapeutic vaccines.
  • Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global MS therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MS therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global MS therapeutics market from 2014-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
    • 3.2.1. Relapse-Remitting Multiple Sclerosis
    • 3.2.2. Secondary Progressive Multiple Sclerosis
    • 3.2.3. Primary Progressive Multiple Sclerosis
    • 3.2.4. Progressive Relapsing Multiple Sclerosis
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. Family members of MS patients have a 1-5% risk of developing MS
    • 4.2.2. Women are twice as likely to develop MS, but men have a worse prognosis
    • 4.2.3. Caucasians have a higher risk of MS than any other race/ethnicity
    • 4.2.4. Protective effect of vitamin D on MS may relate to latitude and month of birth
    • 4.2.5. Timing of environmental exposures affects MS risk
    • 4.2.6. Exposure to smoking may increase MS risk and worsen prognosis
    • 4.2.7. Autoimmune Disease Comorbidities of MS
    • 4.2.8. Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates
  • 4.3. Global Trends
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast of Multiple Sclerosis (2014-2024)
    • 4.5.1. Diagnosed Prevalent Cases of MS
    • 4.5.2. Age-Specific Diagnosed Prevalent Cases of MS
    • 4.5.3. Sex-Specific Diagnosed Prevalent Cases of MS
    • 4.5.4. Diagnosed Incident Cases of MS
    • 4.5.5. Age-Specific Diagnosed Incident Cases of MS
    • 4.5.6. Sex-Specific Diagnosed Incident Cases of MS
    • 4.5.7. MS Subtypes
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis
  • 5.2. Treatment Overview
    • 5.2.1. Management of Acute Relapse
    • 5.2.2. Treatment with Disease-Modifying Therapies
    • 5.2.3. Symptomatic Therapies
  • 5.3. US
    • 5.3.1. Diagnosis
    • 5.3.2. Drug Treatment
  • 5.4. France
    • 5.4.1. Diagnosis
    • 5.4.2. Drug Treatment
  • 5.5. Germany
    • 5.5.1. Diagnosis
    • 5.5.2. Drug Treatment
  • 5.6. Italy
    • 5.6.1. Diagnosis
    • 5.6.2. Drug Treatment
  • 5.7. Spain
    • 5.7.1. Diagnosis
    • 5.7.2. Drug Treatment
  • 5.8. UK
    • 5.8.1. Diagnosis
    • 5.8.2. Drug Treatment
  • 5.9. Japan
    • 5.9.1. Diagnosis
    • 5.9.2. Drug Treatment
  • 5.10. Canada
    • 5.10.1. Diagnosis
    • 5.10.2. Drug Treatment
  • 5.11. China
    • 5.11.1. Diagnosis
    • 5.11.2. Drug Treatment
  • 5.12. India
    • 5.12.1. Diagnosis
    • 5.12.2. Drug Treatment

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Injectable Brands
    • 6.2.1. Betaseron
    • 6.2.2. Avonex
    • 6.2.3. Rebif
    • 6.2.4. Copaxone
    • 6.2.5. Tysabri
    • 6.2.6. Lemtrada
    • 6.2.7. Plegridy
  • 6.3. Product Profiles - Major Small Molecule Brands
    • 6.3.1. Gilenya
    • 6.3.2. Aubagio
    • 6.3.3. Tecfidera
  • 6.4. Other Disease-Modifying Therapies
    • 6.4.1. Overview

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Curative Therapies
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. The High Cost of MS Drugs
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Safety and Tolerability of Therapy
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Effective Treatments for Progressive MS
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Inconvenient Route of Administration and Frequent Dosing
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. MS Biomarkers for Early Diagnosis and Treatment Choice
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Zinbryta
    • 8.3.2. Ocrelizumab
    • 8.3.3. Ofatumumab
    • 8.3.4. Opicinumab
    • 8.3.5. Nerventra
    • 8.3.6. Masitinib
    • 8.3.7. Siponimod
    • 8.3.8. Ozanimod
    • 8.3.9. Ponesimod
  • 8.4. Late-Stage Therapeutic Vaccines
    • 8.4.1. NeuroVax
    • 8.4.2. Tcelna
  • 8.5. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Biogen
    • 9.3.2. Teva
    • 9.3.3. Merck Serono (EMD Serono)
    • 9.3.4. Sanofi (Genzyme)
    • 9.3.5. Bayer
    • 9.3.6. Novartis
    • 9.3.7. Roche

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Canada
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. China
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. India
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed MS Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Launch and Patent Expiry Dates
    • 11.4.4. General Pricing Assumptions
    • 11.4.5. Individual Drug Assumptions
    • 11.4.6. Generic Erosion
    • 11.4.7. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Director of Therapy Research and Analysis
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Common Presenting Symptoms of MS
  • Table 2: Factors That Can Affect Prognosis in MS
  • Table 3: Risk Factors and Comorbidities for MS
  • Table 4: Sources of MS Diagnosed Prevalence and Diagnosed Incidence Data Used in the Epidemiology Forecast
  • Table 5: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Table 6: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N (Row %), 2014
  • Table 7: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, by Sex, N (Row %), 2014
  • Table 8: 10MM, Diagnosed Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Table 9: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N (Row %), 2014
  • Table 10: 10MM, Diagnosed Incident Cases of MS, by Sex, N (Row %), 2014
  • Table 11: Revised 2010 McDonald Criteria for the Diagnosis of MS
  • Table 12: Treatment Guidelines for MS
  • Table 13: Top Three Disease-Modifying Therapies Prescribed for MS by Market
  • Table 14: Pharmacotherapy for Common MS Symptoms
  • Table 15: US - MS Diagnosis Metrics
  • Table 16: US - MS Treatment Metrics
  • Table 17: France - MS Diagnosis Metrics
  • Table 18: France - MS Treatment Metrics
  • Table 19: Germany - MS Diagnosis Metrics
  • Table 20: Germany - MS Treatment Metrics
  • Table 21: Italy - MS Diagnosis Metrics
  • Table 22: Italy - MS Treatment Metrics
  • Table 23: Spain - MS Diagnosis Metrics
  • Table 24: Spain - MS Treatment Metrics
  • Table 25: UK - MS Diagnosis Metrics
  • Table 26: UK - MS Treatment Metrics
  • Table 27: Japan - MS Diagnosis Metrics
  • Table 28: Japan - MS Treatment Metrics
  • Table 29: Canada - MS Diagnosis Metrics
  • Table 30: Canada - MS Treatment Metrics
  • Table 31: China - MS Diagnosis Metrics
  • Table 32: China - MS Treatment Metrics
  • Table 33: India - MS Diagnosis Metrics
  • Table 34: India - MS Treatment Metrics
  • Table 35: Leading Disease-Modifying Drugs for the Treatment of MS, 2015
  • Table 36: Product Profile - Betaseron
  • Table 37: Betaseron SWOT Analysis, 2015
  • Table 38: Global Sales Forecasts ($m) for Betaseron, 2014-2024
  • Table 39: Product Profile - Avonex
  • Table 40: Avonex SWOT Analysis, 2015
  • Table 41: Global Sales Forecasts ($m) for Avonex, 2014-2024
  • Table 42: Product Profile - Rebif
  • Table 43: Rebif SWOT Analysis, 2014
  • Table 44: Global Sales Forecasts ($m) for Rebif, 2014-2024
  • Table 45: Product Profile - Copaxone
  • Table 46: Copaxone SWOT Analysis, 2015
  • Table 47: Global Sales Forecasts ($m) for Copaxone, 2014-2024
  • Table 48: Product Profile - Tysabri
  • Table 49: Tysabri SWOT Analysis, 2015
  • Table 50: Global Sales Forecasts ($m) for Tysabri, 2014-2024
  • Table 51: Product Profile - Lemtrada
  • Table 52: Lemtrada SWOT Analysis, 2015
  • Table 53: Global Sales Forecasts ($m) for Lemtrada, 2014-2024
  • Table 54: Product Profile - Plegridy
  • Table 55: Clinical and MRI Endpoints at Year 1 from a Phase III Trial of Plegridy in MS
  • Table 56: Clinical and MRI Endpoints at Year 2 from a Phase III Trial of Plegridy in MS
  • Table 57: Adverse Events During Year 1 of a Phase III Trial of Plegridy in MS
  • Table 58: Plegridy SWOT Analysis, 2015
  • Table 59: Global Sales Forecasts ($m) for Plegridy, 2014-2024
  • Table 60: Product Profile - Gilenya
  • Table 61: Gilenya SWOT Analysis, 2015
  • Table 62: Global Sales Forecasts ($m) for Gilenya, 2014-2024
  • Table 63: Product Profile - Aubagio
  • Table 64: Aubagio SWOT Analysis, 2015
  • Table 65: Global Sales Forecasts ($m) for Aubagio, 2014-2024
  • Table 66: Product Profile - Tecfidera
  • Table 67: Tecfidera SWOT Analysis, 2015
  • Table 68: Global Sales Forecasts ($m) for Tecfidera, 2014-2024
  • Table 69: Summary of Alternative MS DMTs, 2014
  • Table 70: Unmet Need and Opportunity in MS
  • Table 71: Product Profile - Zinbryta High-Yield Process
  • Table 72: Adverse Events during Year 1 of a Phase III trial of Zinbryta in MS
  • Table 73: Zinbryta SWOT Analysis, 2015
  • Table 74: Global Sales Forecasts ($m) for Zinbryta, 2014-2024
  • Table 75: Product Profile - Ocrelizumab
  • Table 76: Ocrelizumab SWOT Analysis, 2015
  • Table 77: Global Sales Forecasts ($m) for ocrelizumab, 2014-2024
  • Table 78: Product Profile - Ofatumumab
  • Table 79: Ofatumumab SWOT Analysis, 2015
  • Table 80: Global Sales Forecasts ($m) for Ofatumumab, 2014-2024
  • Table 81: Product Profile - Opicinumab
  • Table 82: Opicinumab SWOT Analysis, 2015
  • Table 83: Product Profile - Nerventra
  • Table 84: Nerventra SWOT Analysis, 2015
  • Table 85: Global Sales Forecasts ($m) for Nerventra, 2014-2024
  • Table 86: Product Profile - Masitinib
  • Table 87: Masitinib SWOT Analysis, 2015
  • Table 88: Global Sales Forecasts ($m) for Masitinib, 2014-2024
  • Table 89: Product Profile - Siponimod
  • Table 90: Siponimod SWOT Analysis, 2015
  • Table 91: Global Sales Forecasts ($m) for siponimod, 2014-2024
  • Table 92: Product Profile - Ozanimod
  • Table 93: Ozanimod SWOT Analysis, 2015
  • Table 94: Global Sales Forecasts ($m) for Ozanimod, 2014-2024
  • Table 95: Product Profile - Ponesimod
  • Table 96: Efficacy Results for Ponesimod in a Phase IIb MS Trial
  • Table 97: Ponesimod SWOT Analysis, 2015
  • Table 98: Global Sales Forecasts ($m) for Ponesimod, 2014-2024
  • Table 99: Product Profile - NeuroVax
  • Table 100: NeuroVax SWOT Analysis, 2015
  • Table 101: Product Profile - Tcelna
  • Table 102: Tcelna SWOT Analysis, 2015
  • Table 103: Drugs in Development, 2015
  • Table 104: Key Companies in the MS Market, 2015
  • Table 105: Biogen's Multiple Sclerosis Portfolio Assessment, 2015
  • Table 106: Biogen SWOT Analysis, 2015
  • Table 107: Teva's MS Portfolio Assessment, 2015
  • Table 108: Teva SWOT Analysis, 2015
  • Table 109: Merck's Multiple Sclerosis Portfolio Assessment, 2015
  • Table 110: Merck SWOT Analysis, 2015
  • Table 111: Sanofi's Multiple Sclerosis Portfolio Assessment, 2015
  • Table 112: Sanofi SWOT Analysis, 2015
  • Table 113: Bayer's MS Portfolio Assessment, 2015
  • Table 114: Bayer SWOT Analysis, 2015
  • Table 115: Novartis' MS Portfolio Assessment, 2015
  • Table 116: Novartis SWOT Analysis, 2015
  • Table 117: Roche's Multiple Sclerosis Portfolio Assessment, 2015
  • Table 118: Roche SWOT Analysis, 2015
  • Table 119: Global Sales Forecast ($m) for MS, 2014-2024
  • Table 120: Global MS Market - Drivers and Barriers, 2014-2024
  • Table 121: Sales Forecast ($m) for MS in the United States, 2014-2024
  • Table 122: Key Events Impacting Sales for MS in the US, 2014-2024
  • Table 123: MS Market in the US - Drivers and Barriers, 2014-2024
  • Table 124: Sales Forecasts ($m) for MS in the 5EU, 2014-2024
  • Table 125: Key Events Impacting Sales for MS in the 5EU, 2014-2024
  • Table 126: MS Market in the 5EU - Drivers and Barriers, 2014-2024
  • Table 127: Sales Forecasts ($m) for MS in the Japan, 2014-2024
  • Table 128: Key Events Impacting Sales for MS in Japan, 2014-2024
  • Table 129: MS Market in Japan - Drivers and Barriers, 2014-2024
  • Table 130: Sales Forecasts ($m) for MS in the Canada, 2014-2024
  • Table 131: Key Events Impacting Sales for MS in Canada, 2014-2024
  • Table 132: MS Market in Canada - Drivers and Barriers, 2014-2024
  • Table 133: Sales Forecasts ($m) for MS in the China, 2014-2024
  • Table 134: Key Events Impacting Sales for MS in China, 2014-2024
  • Table 135: MS Market in China - Drivers and Barriers, 2014-2024
  • Table 136: Sales Forecasts ($m) for MS in the India, 2014-2024
  • Table 137: Key Events Impacting Sales for MS in India, 2014-2024
  • Table 138: MS Market in India - Drivers and Barriers, 2014-2024
  • Table 139: Key Launch Dates
  • Table 140: Key Patent Expiries
  • Table 141: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Accrual of Disability in the Four Subtypes of MS
  • Figure 2: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Figure 3: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N, 2014
  • Figure 4: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, by Sex, N, 2014
  • Figure 5: 10MM, Diagnosed Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Figure 6: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N, 2014
  • Figure 7: 10MM, Diagnosed Incident Cases of MS, by Sex, N, 2014
  • Figure 8: 10MM, MS Subtype Distributions, %*, 2014
  • Figure 9: Expanded Disability Status Scale (EDSS)
  • Figure 10: Algorithm for the Treatment of MS with Disease-Modifying Therapies
  • Figure 11: MS Therapeutics - Clinical Trials by Country, 2015
  • Figure 12: Multiple Sclerosis - Phase II-III Pipeline, 2015
  • Figure 13: Competitive Assessment of Late-Stage Pipeline Agents in MS, 2014-2024
  • Figure 14: Multiple Sclerosis - Phase II-III Therapeutic Vaccines, 2015
  • Figure 15: Company Portfolio Gap Analysis in MS, 2014-2024
  • Figure 16: Global Sales for MS by Region, 2014-2024
  • Figure 17: Global Sales for MS by Therapy Type, 2014-2024
  • Figure 18: Sales for MS in the United States by Therapy Type, 2014-2024
  • Figure 19: Sales for MS in the 5EU by Therapy Type, 2014-2024
  • Figure 20: Sales for MS in Japan by Therapy Type, 2014-2024
  • Figure 21: Sales for MS in Canada by Therapy Type, 2014-2024
  • Figure 22: Sales for MS in China by Therapy Type, 2014-2024
  • Figure 23: Sales for MS in India by Drug Class, 2014-2024
Back to Top